

Listing of Claims

This following listing of claims will replace all prior versions and listings of claims in the application.

1. **(currently amended)** A method for treating drug dependence in a subject-a metabotropic glutamate disorder, comprising administering to a subject with drug dependence in need thereof, an effective amount of (a) a first antagonist which modulates metabotropic glutamate receptor 2 and/or metabotropic glutamate receptor 3, and (b) a second antagonist which modulates metabotropic glutamate receptor 5, thereby treating the disorder; wherein the drug dependence-metabotropic glutamate disorder is selected from the group consisting of nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.

2. **(currently amended)** A method for treating drug dependence in a subject-a metabotropic glutamate disorder, comprising administering to a subject with drug dependence in need thereof, an effective amount of (a) a first antagonist which modulates metabotropic glutamate receptor 2, and (b) a second antagonist which modulates metabotropic glutamate receptor 5, thereby treating the disorder; wherein the drug dependence-metabotropic glutamate disorder is selected from the group consisting of nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.

3. **(currently amended)** A method for treating drug dependence in a subject-a metabotropic glutamate disorder, comprising administering to a subject with drug dependence in need thereof an effective amount (a) a first antagonist which modulates metabotropic glutamate receptor 3 and (b) a second antagonist which modulates metabotropic glutamate receptor 5, thereby treating the disorder; wherein the drug

~~dependence-metabotropic glutamate disorder~~ is selected from the group consisting of nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.

4-5. (canceled)

6. **(currently amended)** The method of claim 1, wherein the drug dependence disorder is nicotine addiction.

7. **(currently amended)** The method of claim 1, wherein the drug dependence disorder is cocaine addiction.

8. (canceled)

9. (previously presented) The method according to claim 1, wherein the antagonist which modulates metabotropic glutamate receptor 5 is 2-methyl-6-(phenylethynyl)-pyridine, and the antagonist which modulates metabotropic glutamate receptor 2 and/or metabotropic glutamate receptor 3 is 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic acid .

10. (withdrawn) A combination comprising (a) at least a first active ingredient selected from a metabotropic glutamate receptor 2 antagonist and a metabotropic glutamate receptor 3 antagonist, and (b) at least a second active ingredient being a metabotropic glutamate receptor 5 antagonist, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

11-13. (canceled)

14. (withdrawn) The combination according to claim 10 which is a combined preparation or a pharmaceutical composition.

15. (withdrawn) The combination according to claim 10 for simultaneous, separate or sequential use in the treatment of an addictive disorder or depression.

16. (previously presented) A method of treating a warm-blooded animal having an addictive disorder comprising administering to the animal a combination according to claim 10 in a quantity which is jointly therapeutically effective against an addictive disorder and in which the compounds can also be present in the form of their pharmaceutically acceptable salts; wherein the addictive disorder is selected from the group consisting of nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.

17. (withdrawn) A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against an addictive disorder or depression, of a pharmaceutical combination according to claim 10 and at least one pharmaceutically acceptable carrier.

18. (canceled)

19. **(withdrawn and currently amended)** A commercial package comprising a combination according to claim 10 together with instructions for simultaneous, separate or sequential use thereof in the treatment of an addictive disorder ~~or depression~~.

20-26. (canceled)

27. **(currently amended)** A method for treating an addictive disorder, comprising: a) administering to a subject in need thereof, an effective amount of a first antagonist that modulates mGluR5 during a first time period, wherein the first time

period is a time period wherein the subject expects to be in an environment wherein, or exposed to stimuli in the presence of which, the subject habitually uses an addictive substance; and b) administering a second antagonist that modulates mGluR2 and/or 3 during a second time period, wherein the second time period is a time period wherein the subject is suffering from withdrawal ~~and/or depression~~; wherein the addictive disorder is selected from the group consisting of nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.

28. (previously presented) The method of claim 27, wherein the antagonist that modulates mGluR5 is 2-methyl-6-(phenylethynyl)-pyridine and the antagonist that modulates mGluR2 and/or 3 is 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic acid.

29-31. (canceled)

32. (previously presented) The method of claim 1, wherein the first antagonist and the second antagonist are administered to the subject sequentially or simultaneously.

33. (canceled)